PV Bulletin

Variations Requiring Assessment (Veterinary Medicines) - Q&A Update

The EMA updates its procedural Q&A for veterinary medicines, adding Question 23 regarding variations requiring assessment.

Primary source: Guidance to applicants / marketing authorisation holders on oral explanations at CVMP

PV Impact Brief

Urgency: HighConfidence: high

What changed

Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.

Why it matters

This update enables MAHs to better navigate the requirements for submitting variations, streamlining the process for regulatory compliance in handling veterinary medicinal products.

Action needed

MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review whenever updates to EMA guidance are published.

Policy change details

Document type
Q&A
Policy status
revised
Publication date
2026-07-03
Policy change
The EMA has updated its Q&A on variations requiring assessment for veterinary medicines by adding Question 23.

Key changes

Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsPharmacovigilance

PV impact

Minor procedural update for veterinary MAH regulatory teams handling variations.

View regulator source

Source document details

Exact policy details

Submission of variations
Centrally authorised veterinary medicines require assessment under Regulation (EU) 2019/6.
Applies to: Applies to all marketing authorisation holders submitting variations for centrally authorised veterinary medicines.
This page provides guidance on how to apply for a variation on centrally authorised veterinary medicines requiring assessment under the Veterinary Medicinal Products Regulation. · p. 1 · High · Source
Electronic submission
Mandatory submission via the EMA e-Submission Gateway or Syncplicity Web Client.
Applies to: All submissions to the EMA related to applications for central marketing authorisation.
Electronic submission via the EMA e-Submission Gateway or Syncplicity Web Client is mandatory. · p. 1 · High · Source
Worksharing procedures
Complete dossier must be submitted via Gateway/Syncplicity Web Client for each centrally authorised product.
Applies to: Applies to worksharing procedures for centrally authorized products and nationally authorized products.
For worksharing procedures, the complete dossier should be submitted via the Gateway/Syncplicity Web Client for each centrally authorised product included in the worksharing procedure. · p. 2 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 3, 2026

Full briefing

Practical implication

MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.

The European Medicines Agency (EMA) has added Question 23 to its Q&A on variations requiring assessment (VRA) for veterinary medicines, involving a minor procedural update for marketing authorisation holders (MAHs) handling such variations.

What changed: Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.

Why it matters: This update enables MAHs to better navigate the requirements for submitting variations, streamlining the process for regulatory compliance in handling veterinary medicinal products.

Practical implication: MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Veterinary Medicines#Variations#Q&A#revised#European Medicines Agency#Guidance#policy-change#firecrawl-policy-agent

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward